Mechanistic inferences from clinical reports of SARS-CoV-2. Issue 8 (2nd August 2020)

• Record Type: Journal Article
• Authors: Jenkins, Meagan M.; McCaw, Tyler R.; Goepfert, Paul A.
• Is Part Of: Infectious diseases. Volume 52:Issue 8(2020)
• Page Start: 527
• Page End: 537
• Publication Date: 2020-08-02
• Subjects: SARS-CoV-2 -- COVID-19 -- COVID-19 pneumonia -- immune response -- COVID-19 mechanisms; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; 616.9
• DOI: 10.1080/23744235.2020.1769853
• Languages: English
• ISSNs: 2374-4235

Abstract

Abstract: SARS-CoV-2 was identified as the causative pathogen in an outbreak of viral pneumonia cases originating in Wuhan, China, with an ensuing rapid global spread that led it to be declared a pandemic by the WHO on March 11, 2020. Given the threat to public health posed by sequelae of SARS-CoV-2 infection, the literature surrounding patient presentation in severe and non-severe cases, transmission rates and routes, management strategies, and initial clinical trial results have become available at an unprecedented pace. In this review we collate current clinical and immunologic reports, comparing these to reports of previous coronaviruses to identify mechanisms driving progression to severe disease in some patients. In brief, we propose a model wherein dysregulated type I interferon signalling leads to aberrant recruitment and accumulation of innate immune lineages in the lung, impairing establishment of productive adaptive responses, and permitting a pathologic pro-inflammatory state. Finally, we extend these findings to suggest possible treatment options that may merit investigation in randomized clinical trials.